$55 million settlement for group of health insurers that overpaid for Lupron including Humana, CIGNA and others

Case Abstract
Negiotiated set-aside settlement of $55 million for a group of third party payers who overpaid for Lupron as a result of TAP Pharmaceuticals Products' improper marketing practices for the drug Lupron.

Client
Group of health insurers that overpaid for Lupron including Humana, CIGNA and others.

Case Name
In re Lupron Marketing and Sales Practices Litigation, No. 01-cv-1061(D. Mass.).

Result
$55 million settlement.

Case Details
Led by Richard Cohen and Gerald Lawrence (then with Aetna) Lowey Dannenberg negotiated a preferred set-aside settlement of $55 million for its clients and the clients of cooperating law firms. In the complaint, Lowey Dannenberg alleged that charge that TAP Pharmaceutical Products, Inc., Abbott Laboratories and Takeda Pharmaceuticals conspired to fraudulently market and distribute Lupron by inflating the Average Wholesale Price for the drug causing third party payers to overpay for the drug.